This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gavrilovic, I. T. Articles by Abrey, L. E. Search for Related Content PubMed PubMed Citation Articles by Gavrilovic, I. T. Articles by Abrey, L. E. Social Bookmarking                            What's this?

Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma

Igor T. Gavrilovic, Adília Hormigo, Joachim Yahalom, Lisa M. DeAngelis, Lauren E. Abrey

From the Departments of Neurology and Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Lauren E. Abrey, MD, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: abreyl{at}mskcc.org

PURPOSE: We previously reported a series of patients treated with high-dose methotrexate (MTX) -based chemotherapy, with or without whole brain radiotherapy. The purpose of this report is to update the initial results and provide long-term data regarding overall survival, patterns of relapse, and the risk of treatment-related neurotoxicity.

PATIENTS AND METHODS: Fifty-seven patients with an average age of 65 and median Karnofsky performance score of 70 were treated; all patients have been observed longitudinally with serial magnetic resonance imaging scans and neurologic examinations.

RESULTS: The overall median survival was 51 months with a median follow-up of 115 months for surviving patients. Twenty-five patients relapsed or developed progressive disease; median progression-free survival was 129 months. Seventeen patients developed treatment-related neurotoxicity; all but one had received whole brain radiotherapy as a component of treatment. Seventy-four percent of patients younger than 60 years who received both MTX-based chemotherapy and whole brain radiotherapy were alive at last follow-up. Median survival for patients older than 60 years was 29 months regardless of whether or not they received whole brain radiotherapy.

CONCLUSION: Long-term follow-up of our initial cohort confirms the observation of excellent overall survival, particularly for those patients younger than age 60 at diagnosis. For older patients, it appears to be reasonable to defer whole brain radiotherapy in an effort to minimize treatment-related neurotoxicity.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Ghesquieres, C. Ferlay, C. Sebban, D. Perol, A. Bosly, O. Casasnovas, O. Reman, B. Coiffier, H. Tilly, P. Morel, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Ann. Onc., November 18, 2009; (2009) mdp529v2. [Abstract] [Full Text] [PDF]

				L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al. Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509. [Abstract] [Full Text] [PDF]

				M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan Primary CNS Lymphoma in Immunocompetent Patients Oncologist, May 1, 2009; 14(5): 526 - 539. [Abstract] [Full Text] [PDF]

				Y.-X. Li, Q.-F. Liu, H. Fang, S.-N. Qi, H. Wang, W.-H. Wang, Y.-W. Song, J. Lu, J. Jin, S.-L. Wang, et al. Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma Clin. Cancer Res., April 15, 2009; 15(8): 2905 - 2912. [Abstract] [Full Text] [PDF]

				C. Kadoch, E. B. Dinca, R. Voicu, L. Chen, D. Nguyen, S. Parikh, J. Karrim, M. A. Shuman, C. A. Lowell, P. A. Treseler, et al. Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model Clin. Cancer Res., March 15, 2009; 15(6): 1989 - 1997. [Abstract] [Full Text] [PDF]

				G. Illerhaus, R. Marks, F. Muller, G. Ihorst, F. Feuerhake, M. Deckert, C. Ostertag, and J. Finke High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study Ann. Onc., February 1, 2009; 20(2): 319 - 325. [Abstract] [Full Text] [PDF]

				J.-J. Zhu, E. R. Gerstner, D. A. Engler, M. M. Mrugala, W. Nugent, K. Nierenberg, F. H. Hochberg, R. A. Betensky, and T. T. Batchelor High-dose methotrexate for elderly patients with primary CNS lymphoma Neuro-oncol, January 1, 2009; 11(2): 211 - 215. [Abstract] [Full Text] [PDF]

				K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma Neuro-oncol, January 1, 2009; 11(5): 503 - 513. [Abstract] [Full Text] [PDF]

				Y. Shibamoto, H. Ogino, G. Suzuki, M. Takemoto, N. Araki, K. Isobe, E. Tsuchida, K. Nakamura, M. Kenjo, K. Suzuki, et al. Primary central nervous system lymphoma in Japan: Changes in clinical features, treatment, and prognosis during 1985-2004 Neuro-oncol, August 1, 2008; 10(4): 560 - 568. [Abstract] [Full Text] [PDF]

				R. Yamanaka, K. Morii, Y. Shinbo, J. Homma, M. Sano, N. Tsuchiya, N. Yajima, T. Tamura, H. Hondoh, H. Takahashi, et al. Results of Treatment of 112 Cases of Primary CNS Lymphoma Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 373 - 380. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report Blood, February 1, 2008; 111(3): 1085 - 1093. [Abstract] [Full Text] [PDF]

				G. D. Shah, J. Yahalom, D. D. Correa, R. K. Lai, J. J. Raizer, D. Schiff, R. LaRocca, B. Grant, L. M. DeAngelis, and L. E. Abrey Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma J. Clin. Oncol., October 20, 2007; 25(30): 4730 - 4735. [Abstract] [Full Text] [PDF]

				A. F. Hottinger, L. M. DeAngelis, J. Yahalom, and L. E. Abrey Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma Neurology, September 11, 2007; 69(11): 1178 - 1182. [Abstract] [Full Text] [PDF]

				C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma Clin. Cancer Res., April 15, 2007; 13(8): 2504 - 2511. [Abstract] [Full Text] [PDF]